DekaBank Deutsche Girozentrale Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DekaBank Deutsche Girozentrale boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 221,176 shares of the biopharmaceutical company's stock after purchasing an additional 9,969 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.20% of Regeneron Pharmaceuticals worth $139,484,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the period. Finally, Tompkins Financial Corp purchased a new position in Regeneron Pharmaceuticals during the first quarter worth about $32,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 2.0%

NASDAQ REGN traded up $10.77 during trading on Tuesday, reaching $548.88. The company's stock had a trading volume of 58,198 shares, compared to its average volume of 904,334. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The business has a 50-day moving average price of $547.93 and a 200-day moving average price of $623.60. The stock has a market capitalization of $59.26 billion, a PE ratio of 13.97, a PEG ratio of 2.00 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the firm earned $9.55 EPS. The firm's revenue was down 3.7% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Royal Bank Of Canada lowered Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research report on Friday, May 30th. The Goldman Sachs Group cut their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Finally, Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $822.58.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.